An ACR Convergence 2022 session provided practical updates on ways to best protect pediatric & adult patients with rheumatic disease from COVID-19.
Search results for: Janus kinase inhibitors
COVID-19 Vaccinations in Immune-Compromised Patients
A prospective observational study by Syversen et al. found that patients with immune-mediated inflammatory diseases (IMID) had an attenuated serologic response to the standard two-dose vaccine regimen but a third dose was safe and effective.
Difficult-to-Treat Lupus: When & How to Use New Therapies
Clinicians have numerous treatment options for SLE; in a EULAR 2022 session, some of the newer therapies were reviewed.
Remission Definitions in RA: Common Questions & Implications for Clinical Practice
A recent editorial provides new insights by reexamining the definitions of remission for rheumatoid arthritis and outlining concerns with the use of specific metrics for remission in clinical trials.
How Do Axial SpA & PsA with Axial Involvement Differ?
The differences between axial spondyloarthropathy (axSpA) and axial involvement in psoriatic arthritis (axPsA) have clinical and therapeutic implications. Three experts discussed the distinctions during ACR Convergence 2021.
New Findings on COVID-19 Vaccination, Race & More Shared in 1st Plenary Session
Researchers shared findings on the immune response to COVID-19 vaccination in immunocompromised patients, insights into cognitive impairment in SLE & more.
Joint Venture: 2021 Updates in Rheumatoid Arthritis
An update on the state of RA management was presented by Dr. Bryant England, a co-author of the 2021 ACR Guideline on the Management of Rheumatoid Arthrits, during the Review Course held during ACR Convergence 2021.
Clinical Rheumatology Year in Review 2021
ACR Convergence 2021—On Nov. 5, Karen H. Costenbader, MD, MPH, professor of medicine, Harvard Medical School, and director of the lupus program, Brigham and Women’s Hospital, Boston, gave a whirlwind review of the most important clinical rheumatology publications of the past year. Testing New Medications for Rheumatic Disease ADVOCATE Trial of Avacopan Dr. Costenbader first…
From Contraception to Breastfeeding: Experts Address Reproductive Health & Medication Management
ACR CONVERGENCE 2021—Rheumatologists are often left in a challenging space when managing medications for patients with rheumatic diseases in relation to contraception, pregnancy and breastfeeding, especially with many novel immunosuppressants and often a dearth of pregnancy safety data. On Nov. 6 during ACR Convergence 2021, leading reproductive health experts came together to speak on this…
20 Years of RA Data: First-Line Biologic & Targeted Synthetic DMARD Trends
Data from a single-center registry shines light on 20 years of trends in first-line, biologic disease-modifying anti-rheumatic drug prescriptions for patients with rheumatoid arthritis.
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 17
- Next Page »